Instrument Inactif

Autres langues Osiris Therapeutics, Inc.

Actions

US68827R1086

Recherche biotechnologique et médicale

Autres langues

17/04/19	Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc
12/03/19	OSIRIS THERAPEUTICS, INC. Rigrodsky & Long, P.A. Announces Investigation of Buyout
12/03/19	Johnson & Johnson : Smith & Nephew to buy Osiris in regenerative products push
12/03/19	Osiris Therapeutics : Smith & Nephew expands in high growth regenerative medicine market through acquisition of Osiris Therapeutics, Inc.
12/03/19	Osiris Therapeutics, Inc. Enters Agreement to be Acquired by Smith & Nephew plc
24/01/19	Hagens Berman: Notice to Osiris Therapeutics, Inc. Investors: Less than One Week Left to File Claims to Receive Part of $18.5 Million Settlement
16/01/19	Osiris Therapeutics : Hagens Berman Notifies Osiris Therapeutics, Inc. Investors of Class Action Settlement and January 30, 2019 Claims Deadline
26/11/18	Osiris Therapeutics, Inc. Appoints Samson Tom, PhD, MBA to Serve as President and Chief Executive Officer
07/11/18	Osiris Therapeutics, Inc Reports Third Quarter 2018 Results
06/02/18	Osiris Appoints Willi Miesch to its Board of Directors, Change in CEO
02/11/17	Osiris Therapeutics, Inc. Announces Resolution of SEC Investigation
30/10/17	Osiris Therapeutics, Inc. Provides Update on Audit of 2015 and 2016 Financial Statements
23/10/17	Osiris Announces a Peer-Reviewed Publication of a Scientific Study Reporting Antimicrobial Properties of Human Cryopreserved Viable Amniotic Membrane
19/10/17	Osiris Therapeutics to Present 10 Advanced Clinical and Scientific Abstracts, Including an Exclusive Oral Presentation on its New Ambient Viable Tissue Preservation Technology
05/10/17	Osiris Announces a Peer-Reviewed Publication Reporting the Use of Placental Membranes for Refractory Cutaneous Sinus Tracts of Surgical Origin
26/06/17	Osiris Appoints Linda Palczuk to serve as its President & CEO
14/06/17	Osiris Announces Electronically Available Case Study in a Peer-Reviewed Journal: Open Surgical Implantation of a Viable Cryopreserved Placental Membrane after Decompression and Neurolysis of Common Peroneal Nerve
13/04/17	Osiris Announces Scientific Manuscript Comparing Impact of Preservation Methods on Tissue Integrity and Functionality is Available Electronically in Peer-Reviewed Journal
04/04/17	Osiris Therapeutics to Present 29 Advanced Clinical and Scientific Abstracts, Including a Late-Breaking Abstract on its New Ambient Viable Tissue Preservation Technology
31/03/17	Osiris Therapeutics Announces Change in its Board of Directors
31/03/17	Osiris Therapeutics Launches Prestige™ Lyotechnology, a Novel Method for Ambient Storage of Living Cells and Tissues
27/03/17	Osiris Therapeutics, Inc. Completes Restatement of 2014 Financial Statements
10/03/17	Osiris Receives Notice of Delisting from NASDAQ
10/02/17	Osiris Appoints Uwe Sommer and Thomas Knapp to its Board of Directors
19/01/17	Osiris Therapeutics announced a Comparative Effectiveness Study on the Use of Two Human Placental Membranes in Wound Management is Available Electronically in a Peer-Reviewed Journal